[go: up one dir, main page]

MX2018008061A - Profarmacos de peptido natriuretico tipo c (cnp) con porciones portadoras grandes. - Google Patents

Profarmacos de peptido natriuretico tipo c (cnp) con porciones portadoras grandes.

Info

Publication number
MX2018008061A
MX2018008061A MX2018008061A MX2018008061A MX2018008061A MX 2018008061 A MX2018008061 A MX 2018008061A MX 2018008061 A MX2018008061 A MX 2018008061A MX 2018008061 A MX2018008061 A MX 2018008061A MX 2018008061 A MX2018008061 A MX 2018008061A
Authority
MX
Mexico
Prior art keywords
moiety
cnp
large carrier
carrier moieties
prodrug
Prior art date
Application number
MX2018008061A
Other languages
English (en)
Inventor
Rau Harald
Hersel Ulrich
Cleemann Felix
Elisabeth Rasmussen Caroline
Original Assignee
Ascendis Pharma Growth Disorders As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ascendis Pharma Growth Disorders As filed Critical Ascendis Pharma Growth Disorders As
Publication of MX2018008061A publication Critical patent/MX2018008061A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/2242—Atrial natriuretic factor complex: Atriopeptins, atrial natriuretic protein [ANP]; Cardionatrin, Cardiodilatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4015—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having oxo groups directly attached to the heterocyclic ring, e.g. piracetam, ethosuximide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/58—Atrial natriuretic factor complex; Atriopeptin; Atrial natriuretic peptide [ANP]; Cardionatrin; Cardiodilatin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Endocrinology (AREA)
  • Cardiology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Rheumatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

La presente invención se refiere a un profármaco del CNP o una sal del mismo farmacéuticamente aceptable que comprende una porción del CNP -D; y una porción portadora -Z que está conjugada a través de una porción -L2- a una porción enlazadora de profármaco reversible -L1-, en la cual la porción enlazadora de profármaco reversible -L1- está covalentemente e irreversiblemente conjugada a -D; en donde -L2- es un enlace químico o un espaciador; y -Z es un polímero que tiene un peso molecular de al menos 10 kDa. Además se refiere a composiciones farmacéuticas que comprenden el profármaco del CNP o una sal del mismo farmacéuticamente aceptable, su uso como un medicamento y a métodos de tratamiento.
MX2018008061A 2016-01-08 2017-01-05 Profarmacos de peptido natriuretico tipo c (cnp) con porciones portadoras grandes. MX2018008061A (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
EP16150624 2016-01-08
EP16179286 2016-07-13
EP16191458 2016-09-29
PCT/EP2017/050201 WO2017118693A1 (en) 2016-01-08 2017-01-05 Cnp prodrugs with large carrier moieties

Publications (1)

Publication Number Publication Date
MX2018008061A true MX2018008061A (es) 2018-08-23

Family

ID=57838356

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2018008061A MX2018008061A (es) 2016-01-08 2017-01-05 Profarmacos de peptido natriuretico tipo c (cnp) con porciones portadoras grandes.

Country Status (8)

Country Link
US (6) US10835578B2 (es)
EP (1) EP3400020A1 (es)
JP (4) JP7051686B2 (es)
AU (2) AU2017205268B2 (es)
CA (1) CA3007976C (es)
MX (1) MX2018008061A (es)
WO (1) WO2017118693A1 (es)
ZA (1) ZA201804414B (es)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017118703A1 (en) 2016-01-08 2017-07-13 Ascendis Pharma Growth Disorders A/S Controlled-release cnp agonists with low initial npr-b activity
EP3400020A1 (en) 2016-01-08 2018-11-14 Ascendis Pharma Growth Disorders A/S Cnp prodrugs with large carrier moieties
US11311604B2 (en) * 2016-01-08 2022-04-26 Ascendis Pharma Growth Disorders A/S Controlled-release CNP agonists with low NPR-C binding
CA3008017C (en) 2016-01-08 2024-01-02 Ascendis Pharma Growth Disorders A/S Controlled-release cnp agonists with reduced side-effects
EP4162955A1 (en) 2016-01-08 2023-04-12 Ascendis Pharma Growth Disorders A/S Cnp prodrugs with carrier attachment at the ring moiety
IL259659B (en) 2016-01-08 2022-08-01 Ascendis Pharma Growth Disorders As Controlled-release cnp agonists with increased nep stability
BR112019005351A2 (pt) 2016-09-29 2019-06-11 Ascendis Pharma Growth Disorders As terapia combinada com agonistas de cnp de liberação controlada
JP7152408B2 (ja) 2017-03-10 2022-10-12 キアペグ ファーマシューティカルズ アクチエボラグ 遊離可能コンジュゲート
CN111918665B (zh) * 2018-03-28 2024-11-26 阿森迪斯药物肿瘤股份有限公司 Il-2缀合物
KR20210057130A (ko) 2018-09-12 2021-05-20 퀴아펙 파마슈티칼스 에이비 방출가능한 glp-1 컨쥬게이트
WO2020165081A1 (en) 2019-02-11 2020-08-20 Ascendis Pharma Growth Disorders A/S Dry pharmaceutical formulations of cnp conjugates
TW202210502A (zh) 2020-06-03 2022-03-16 丹麥商阿森迪斯腫瘤製藥有限公司 新穎il-2序列及其用途
IL298992A (en) * 2020-06-12 2023-02-01 Pharmain Corp C-type natriuretic peptides and their methods for cancer treatment
AU2022413318A1 (en) * 2021-12-13 2024-05-16 Ascendis Pharma Growth Disorders A/S Effective doses of cnp conjugates
US20250195617A1 (en) * 2022-05-23 2025-06-19 Ascendis Pharma Growth Disorders A/S Liquid Pharmaceutical Formulations of CNP Compounds
WO2024094747A1 (en) 2022-11-02 2024-05-10 Novo Nordisk A/S Cnp compounds
WO2024104922A1 (en) 2022-11-14 2024-05-23 Ascendis Pharma Growth Disorders A/S Method of improving skeletal muscle function
WO2024194300A1 (en) 2023-03-20 2024-09-26 Ascendis Pharma Growth Disorders A/S Method of treatment of a thoracolumbar deformity in a human subject with achondroplasia

Family Cites Families (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6624142B2 (en) 1997-12-30 2003-09-23 Enzon, Inc. Trimethyl lock based tetrapartate prodrugs
EP1118329A4 (en) 1998-09-28 2004-12-15 Santen Pharmaceutical Co Ltd LACRYMAL SECRETION PROMOTERS OR OPHTHALMOLOGICAL DROPS CONTAINING NATRIURETIC PEPTIDES AS ACTIVE INGREDIENTS FOR TREATING KERATOCONJUNCTIVITY
CA2462930C (en) 2001-10-10 2012-07-10 Shawn De Frees Remodeling and glycoconjugation of peptides
US8596542B2 (en) * 2002-06-04 2013-12-03 Hand Held Products, Inc. Apparatus operative for capture of image data
US7122189B2 (en) 2002-08-13 2006-10-17 Enzon, Inc. Releasable polymeric conjugates based on aliphatic biodegradable linkers
ATE459370T1 (de) 2002-11-26 2010-03-15 Biocon Ltd Modifizierte natriuretic verbindungen, konjugate und ihre verwendungen
US7332164B2 (en) 2003-03-21 2008-02-19 Enzon Pharmaceuticals, Inc. Heterobifunctional polymeric bioconjugates
PL1620118T3 (pl) 2003-04-08 2014-11-28 Yeda Res & Dev Leki odwracalnie pegylowane
MXPA06010782A (es) 2004-03-23 2007-03-28 Complex Biosystems Gmbh Ligador de profarmaco.
GB2427360A (en) 2005-06-22 2006-12-27 Complex Biosystems Gmbh Aliphatic prodrug linker
CU23556A1 (es) * 2005-11-30 2010-07-20 Ct Ingenieria Genetica Biotech Estructura polimérica semejante a dendrímero para la obtención de conjugados de interés farmacéutico
US8450269B2 (en) 2006-02-03 2013-05-28 Prolor Biotech Ltd. Long-acting growth hormone and methods of producing same
WO2008031045A2 (en) 2006-09-08 2008-03-13 Mayo Foundation For Medical Education And Research Aquaretic and natriuretic polypeptides lacking vasodilatory activity
MX2009002859A (es) 2006-09-15 2009-03-30 Enzon Pharmaceuticals Inc Enlazadores biodegradables a base de ester impedido para suministro de oligonucleotidos.
KR20140032505A (ko) 2006-11-09 2014-03-14 알콘 리서치, 리미티드 약물 전달용 수불용성 폴리머 매트릭스
BRPI0810356A2 (pt) * 2007-04-20 2014-10-21 Shell Int Research Sistema de aquecimento para uma formação de subsuperfície, e, método para aquecer uma formação de subsuperfície.
KR20080098216A (ko) 2007-05-04 2008-11-07 한미약품 주식회사 캐리어 물질을 이용한 나트륨 배설 펩타이드 약물 결합체
ES2362386T3 (es) 2007-06-21 2011-07-04 Technische Universität München Proteínas activas biológicas que tienen estabilidad aumentada in vivo y/o in vitro.
TW200922624A (en) 2007-07-11 2009-06-01 Enzon Pharmaceuticals Inc Polymeric drug delivery system containing a multi-substituted aromatic moiety
EP2217620A2 (en) 2007-11-21 2010-08-18 BioMarin Pharmaceutical Inc. Variants of c-type natriuretic peptide
EP2237799B1 (en) * 2008-02-01 2019-04-10 Ascendis Pharma A/S Prodrug comprising a self-cleavable linker
US20110105413A1 (en) 2008-05-23 2011-05-05 Enzon Pharmaceuticals, Inc. Polymeric systems containing intracellular releasable disulfide linker for the delivery of oligonucleotides
WO2009156481A1 (en) 2008-06-25 2009-12-30 Ascendis Pharma As Pegylated bnp
WO2010033216A1 (en) 2008-09-19 2010-03-25 Nektar Therapeutics Polymer conjugates of nesiritide peptides
EA020843B1 (ru) 2009-02-03 2015-02-27 Амуникс Оперейтинг Инк. Удлиненные рекомбинантные полипептиды и содержащие их композиции
TWI471137B (zh) 2009-05-20 2015-02-01 Biomarin Pharm Inc Ｃ型利鈉胜肽變異體
US9173953B2 (en) 2009-07-31 2015-11-03 Ascendis Pharma As Prodrugs containing an aromatic amine connected by an amido bond to a linker
WO2011031441A1 (en) * 2009-08-28 2011-03-17 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Therapy with a chimeric molecule and a pro-apoptotic agent
WO2011075471A2 (en) 2009-12-18 2011-06-23 Alcon Research, Ltd. Novel npr-b agonists and methods of use for the treatment of c-type natriuretic peptide-mediated disorders
EP2519228A4 (en) 2009-12-31 2013-06-19 Enzon Pharmaceuticals Inc POLYMER CONJUGATES FROM AN AROMATIC AMINE WITH COMPOUNDS WITH A CLEANER UREA CONTAINER
WO2011089215A1 (en) 2010-01-22 2011-07-28 Ascendis Pharma As Dipeptide-based prodrug linkers for aromatic amine-containing drugs
WO2011089214A1 (en) 2010-01-22 2011-07-28 Ascendis Pharma As Carrier-linked carbamate prodrug linkers
US9062094B2 (en) 2010-01-22 2015-06-23 Ascendis Pharma As Dipeptide-based prodrug linkers for aliphatic amine-containing drugs
EP3372617B1 (en) 2010-04-02 2024-07-24 Amunix Pharmaceuticals, Inc. Binding fusion proteins, binding fusion protein-drug conjugates, xten-drug conjugates and methods of making and using same
US8754190B2 (en) 2010-05-05 2014-06-17 Prolynx Llc Controlled release from macromolecular conjugates
EP2566334B1 (en) 2010-05-05 2018-04-18 Prolynx, LLC Controlled drug release from solid supports
SI2571510T1 (sl) 2010-05-21 2019-02-28 Xl-Protein Gmbh Biosintetični prolin/alaninski naključno zviti polipeptidi in njihove uporabe
AU2012296949B2 (en) 2011-08-12 2016-09-15 Ascendis Pharma A/S High-loading water-soluble carrier-linked prodrugs
US20140323402A1 (en) 2011-08-12 2014-10-30 Ascendis Phama A/S Protein Carrier-Linked Prodrugs
US20140249093A1 (en) 2011-08-12 2014-09-04 Ascendis Pharma A/S Carrier-Linked Prodrugs Having Reversible Carboxylic Ester Linkages
AU2012296954B2 (en) 2011-08-12 2016-09-15 Ascendis Pharma A/S Carrier-linked treprostinil prodrugs
US20140243254A1 (en) 2011-08-12 2014-08-28 Ascendis Pharma A/S Polymeric Hyperbranched Carrier-Linked Prodrugs
WO2013036857A1 (en) 2011-09-07 2013-03-14 Prolynx Llc Sulfone linkers
HK1205697A1 (zh) 2012-04-25 2015-12-24 Ascendis Pharma A/S 含有羟基的药物的前药
TWI578995B (zh) 2012-04-25 2017-04-21 第一三共股份有限公司 利尿鈉肽受體npr-b促效劑之用途
US10052366B2 (en) 2012-05-21 2018-08-21 Alexion Pharmaceuticsl, Inc. Compositions comprising alkaline phosphatase and/or natriuretic peptide and methods of use thereof
JPWO2015129812A1 (ja) 2014-02-27 2017-03-30 第一三共株式会社 ステロイド剤投与で誘発される成長障害に対する医薬
WO2016020373A1 (en) 2014-08-06 2016-02-11 Ascendis Pharma A/S Prodrugs comprising an aminoalkyl glycine linker
JP2018502868A (ja) 2015-01-09 2018-02-01 アセンディス ファーマ グロース ディスオーダーズ エー／エス Ｃｎｐプロドラッグ
PL3386531T3 (pl) 2015-12-08 2022-02-28 Biomarin Pharmaceutical Inc. Zastosowanie wariantów peptydu natriuretycznego typu c w leczeniu choroby zwyrodnieniowej stawów
WO2017118703A1 (en) 2016-01-08 2017-07-13 Ascendis Pharma Growth Disorders A/S Controlled-release cnp agonists with low initial npr-b activity
EP3400020A1 (en) 2016-01-08 2018-11-14 Ascendis Pharma Growth Disorders A/S Cnp prodrugs with large carrier moieties
IL259659B (en) 2016-01-08 2022-08-01 Ascendis Pharma Growth Disorders As Controlled-release cnp agonists with increased nep stability
EP4162955A1 (en) 2016-01-08 2023-04-12 Ascendis Pharma Growth Disorders A/S Cnp prodrugs with carrier attachment at the ring moiety
US11311604B2 (en) 2016-01-08 2022-04-26 Ascendis Pharma Growth Disorders A/S Controlled-release CNP agonists with low NPR-C binding
CA3008017C (en) 2016-01-08 2024-01-02 Ascendis Pharma Growth Disorders A/S Controlled-release cnp agonists with reduced side-effects
BR112019005351A2 (pt) * 2016-09-29 2019-06-11 Ascendis Pharma Growth Disorders As terapia combinada com agonistas de cnp de liberação controlada
WO2020165081A1 (en) 2019-02-11 2020-08-20 Ascendis Pharma Growth Disorders A/S Dry pharmaceutical formulations of cnp conjugates

Also Published As

Publication number Publication date
JP2021100937A (ja) 2021-07-08
AU2017205268B2 (en) 2022-02-17
ZA201804414B (en) 2019-04-24
US20210177942A1 (en) 2021-06-17
US11154593B2 (en) 2021-10-26
US20190015481A1 (en) 2019-01-17
US20250127859A1 (en) 2025-04-24
EP3400020A1 (en) 2018-11-14
CA3007976A1 (en) 2017-07-13
JP2019507724A (ja) 2019-03-22
US20220296682A1 (en) 2022-09-22
JP6951597B2 (ja) 2021-10-20
US20240316153A1 (en) 2024-09-26
JP2023175776A (ja) 2023-12-12
JP2022088545A (ja) 2022-06-14
US20210077584A1 (en) 2021-03-18
JP7692454B2 (ja) 2025-06-13
AU2022201416A1 (en) 2022-03-24
AU2022201416B2 (en) 2023-06-01
JP7051686B2 (ja) 2022-04-11
AU2017205268A1 (en) 2018-06-07
CA3007976C (en) 2023-09-26
WO2017118693A1 (en) 2017-07-13
US10835578B2 (en) 2020-11-17
JP7350123B2 (ja) 2023-09-25

Similar Documents

Publication Publication Date Title
MX2018008061A (es) Profarmacos de peptido natriuretico tipo c (cnp) con porciones portadoras grandes.
MX2023013592A (es) Conjugados de farmaco con enlazadores autoestabilizantes que tienen propiedades fisioquimicas mejoradas.
WO2015095227A3 (en) Peptidomimetic compounds and antibody-drug conjugates thereof
WO2015095811A8 (en) Combination therapy with neoantigen vaccine
NZ710729A (en) Amatoxin derivatives
MX2024008222A (es) Hidrogeles de acido hialuronico degradables.
EP3566750A3 (en) Conjugates comprising cell-binding agents and cytotoxic agents
MX2020009857A (es) Conjugados de interleucina-2 (il-2).
MX2016015093A (es) Derivados de acido boronico y sus usos terapeuticos.
MX2023002599A (es) Conjugados de compuestos de tubulisina cuaternizada.
HK1206297A1 (en) Pharmaceutical compositions for combination therapy
CY1122899T1 (el) Υδατικη συσταση περιλαμβανουσα παρακεταμολη και ιβουπροφαινη
MX2018001511A (es) Polimeros furtivos desordenados de forma intrinseca codificados geneticamente para suministro y metodos para usar los mismos.
MX2023014492A (es) Compuestos utiles en la terapia para el vih.
IN2014DN08299A (es)
WO2014134457A3 (en) Conjugates comprising cell-binding agents and cytotoxic agents
TN2017000168A1 (en) Substituted 2,4 diamino-quinoline as new anticancer agents
EA201991196A1 (ru) Претерпевшие самосборку диблок-сополимеры, состоящие из pegmema и несущих лекарственное средство полимерных сегментов
PH12018500315A1 (en) Fumagillol heterocyclic compounds and methods of making and using same
MX2019001634A (es) Compuestos amidas, composiciones farmacéuticas de estos y métodos para utilizarlos.
HK1219423A1 (zh) 包含细胞结合剂及细胞毒素剂的轭合物
PH12017501876A1 (en) Pyridopyrimidones and their use as nmda receptor modulators
MX2021003186A (es) Nuevos conjugados de hidrogel.
CY1121345T1 (el) Φαρμακευτικες συνθεσεις και χρησεις που απευθυνονται σε διαταραχες λυσοσωμιακης αποθηκευσης
WO2014035846A3 (en) Substituted azaindole compounds, salts, pharmaceutical compositions thereof and methods of use